Effect of HER2-targeted therapy on PDX and PDX-derived organoids generated from HER2-positive salivary duct carcinoma

被引：2
|
作者：
Aoyama, Jun [1 ]
Nojima, Yusuke [1 ]
Sano, Daisuke [1 ,2 ,3 ]
Hirai, Yuri [1 ]
Kijima, Natsumi [1 ]
Aizawa, Yoshihiro [1 ]
Takada, Kentaro [1 ]
Hatano, Takashi [1 ]
Takahashi, Hideaki [1 ]
Nishimura, Goshi [1 ]
Oridate, Nobuhiko [1 ,2 ]
机构：
[1] Yokohama City Univ, Grad Sch Med, Dept Biol & Funct Head & Neck, Yokohama, Japan
[2] Yokohama City Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Yokohama, Japan
[3] Yokohama City Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, 3-9 Fukuura,Kanazawa Ku, Yokohama 2360004, Japan
来源：
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2023年 / 45卷 / 07期
基金：
日本学术振兴会;
关键词：
HER2; lapatinib; patient-derived organoid; salivary duct carcinoma; salivary gland cancer; FACTOR RECEPTOR EGFR; LAPATINIB; BREAST; TRASTUZUMAB; RESISTANCE; INHIBITOR; GW572016; HEAD;
D O I：
10.1002/hed.27395
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
BackgroundWe previously established a patient-derived xenograft (PDX) model, patient-derived organoids (PDOs), and PDX-derived organoids (PDXOs) for salivary duct carcinoma (SDC). Using these models, this study examined the therapeutic effect of human epidermal growth factor receptor 2 (HER2) blockade on HER2-positive SDC. MethodsThe therapeutic effect of lapatinib was assessed in SDC PDXOs with regards to cell growth, receptor/downstream signaling molecule expression, phosphorylation levels, and apoptosis. Effect of lapatinib treatment was evaluated in vivo in SDC PDX mice. ResultsThe siRNA knockdown of HER2 and lapatinib suppressed cell proliferation in SDC PDXOs. Lapatinib inhibited the phosphorylation of HER2 and its downstream targets, and induced apoptosis in SDC PDXOs. Lapatinib also significantly reduced tumor volumes compared with that of the control in SDC PDX mice. ConclusionFor the first time, we demonstrated the efficacy of anti-HER2 therapy in HER2-positive SDC using preclinical models of SDC PDX and PDXO.
引用
收藏
页码：1801 / 1811
页数：11
相关论文
共 50 条
  • [31] The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
    Lewis, G. D.
    Haque, W.
    Farach, A.
    Hatch, S. S.
    Butler, E. B.
    Schwartz, M. R.
    Bonefas, E.
    Teh, B. S.
    CANCER RESEARCH, 2019, 79 (04)
  • [32] The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
    Lewis, Gary D.
    Haque, Waqar
    Farach, Andrew
    Hatch, Sandra S.
    Butler, E. Brian
    Niravath, Polly A.
    Schwartz, Mary R.
    Bonefas, Elizabeth
    Teh, Bin S.
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2021, 26 (02) : 179 - 187
  • [33] Carnitine palmitoyltransferase IA: an emerging potential metabolic target to counteract HER2-targeted therapy resistance in HER2-positive breast cancer
    Franceschini, Alma
    Castagnoli, Lorenzo T.
    Triulzi, Tiziana Iindt
    Corsetto, Paola Antonia
    Dugo, Matteo
    Belfiore, Antonino
    Vingiani, Andrea
    Signati, Lorena
    Mazzucchelli, Serena
    Corsi, Fabio
    Ligorio, Francesca
    Tagliabue, Elda
    Vernieri, Claudio
    Pupa, Serenella M.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [34] A Phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer heavily pre-treated with HER2-targeted therapy
    Brufsky, Adam
    Zulfiqar, Malik
    Peguero, Julio
    Lathrop, Kate
    Bhat, Gajanan
    Lebel, Francois
    CANCER RESEARCH, 2021, 81 (04)
  • [35] Caspase-3 mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer
    Luo, Qiuyun
    Xia, Zengfei
    Yang, Jing
    Pan, Wentao
    Luo, Fan
    Cao, Jiaxin
    Sun, Yuting
    Yang, Liqiong
    Zhang, Lin
    Qiu, Miaozhen
    Yang, Dajun
    CANCER RESEARCH, 2023, 83 (07)
  • [36] Targeted therapy in HER2-positive breast cancer (Review)
    Li, Shu Guang
    Li, Li
    BIOMEDICAL REPORTS, 2013, 1 (04) : 499 - 505
  • [37] Delayed initiation of HER2-targeted therapy (HER2Tx) is associated with a higher risk of relapse for early stage (ES) HER2-positive (HER2+) breast cancer (BrCa)
    Gullo, G.
    Bose, R.
    Walsh, N.
    Maltese, M.
    Fennelly, D.
    Walshe, J.
    Ballot, J.
    Crown, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] EFFICACY OF HER2-TARGETED THERAPY FOR HER2 POSITIVE BREAST CANCER ACCORDING TO HR STATUS
    Murata, T.
    Takahashi, M.
    Hayashida, T.
    Hirose, S.
    Jinno, H.
    Kitagawa, Y.
    BREAST, 2013, 22 : S104 - S104
  • [39] The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
    Diogo Mendes
    Carlos Alves
    Noémia Afonso
    Fátima Cardoso
    José Luís Passos-Coelho
    Luís Costa
    Sofia Andrade
    Francisco Batel-Marques
    Breast Cancer Research, 17
  • [40] HER2-targeted interferon-beta-1a mutein, a potent immunocytokine for the treatment of HER2-positive cancers.
    Lee, Chan Gyu
    Kim, Tae Eun
    Hong, Sungyoul
    Chu, Jongwan
    Kang, Ju Eun
    Jeong, Hae Min
    Shin, Young Kee
    CANCER RESEARCH, 2021, 81 (13)
12345